Altimmune announces positive topline results from momentum 48-week phase 2 obesity trial of pemvidutide

Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at week 48, with weight loss continuing at the end of treatment over 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at 48 weeks robust reductions in bmi and serum lipids and improvements in blood pressure without imbalances in cardiac events, arrhythmias or clinically meaningful increases in heart rate altimmune to host conference call tomorrow at 8:30 am est gaithersburg, md., nov. 30, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company (the “company”), today announced topline results from its 48-week momentum phase 2 obesity trial of pemvidutide.
ALT Ratings Summary
ALT Quant Ranking